This paper is in the following e-collection/theme issue:

Early Reports (28) Wearable Devices and Sensors (888) Fitness Trackers and Smart Pedometers/Accelerometers (561) Coronary Heart Disease (81)

Published on in Vol 6, No 12 (2017): December

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/8057, first published .
Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial

Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial

Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial

Authors of this article:

Kade Birkeland1 Author Orcid Image ;   Raj M Khandwalla2 Author Orcid Image ;   Ilan Kedan2 Author Orcid Image ;   Chrisandra L Shufelt3 Author Orcid Image ;   Puja K Mehta4 Author Orcid Image ;   Margo B Minissian3 Author Orcid Image ;   Janet Wei3 Author Orcid Image ;   Eileen M Handberg5 Author Orcid Image ;   Louise EJ Thomson6 Author Orcid Image ;   Daniel S Berman6 Author Orcid Image ;   John W Petersen5 Author Orcid Image ;   R David Anderson5 Author Orcid Image ;   Galen Cook-Wiens7 Author Orcid Image ;   Carl J Pepine5 Author Orcid Image ;   C Noel Bairey Merz3 Author Orcid Image
Article Authors Cited by (9) Tweetations (2) Metrics

Journals

  1. Zhu H, Xu X, Fang X, Zheng J, Zhao Q, Chen T, Huang J. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials. Clinical Therapeutics 2019;41(10):2137 View
  2. Barsky L, Merz C, Wei J, Shufelt C, Handberg E, Pepine C, Rutledge T, Reis S, Doyle M, Rogers W, Shaw L, Sopko G. Even “WISE-R?”—an Update on the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation. Current Atherosclerosis Reports 2020;22(8) View
  3. Kofler T, Hess S, Moccetti F, Pepine C, Attinger A, Wolfrum M, Toggweiler S, Kobza R, Cuculi F, Bossard M. Efficacy of Ranolazine for Treatment of Coronary Microvascular Dysfunction—A Systematic Review and Meta-analysis of Randomized Trials. CJC Open 2021;3(1):101 View
  4. Massoomi M, Handberg E. Increasing and Evolving Role of Smart Devices in Modern Medicine. European Cardiology Review 2019;14(3):181 View
  5. Sharp R, Patatanian E, Sirajuddin R. Use of Ranolazine for the Treatment of Coronary Microvascular Dysfunction. American Journal of Cardiovascular Drugs 2021;21(5):513 View
  6. Huhn S, Axt M, Gunga H, Maggioni M, Munga S, Obor D, Sié A, Boudo V, Bunker A, Sauerborn R, Bärnighausen T, Barteit S. The Impact of Wearable Technologies in Health Research: Scoping Review. JMIR mHealth and uHealth 2022;10(1):e34384 View
  7. Ganesananthan S, Rajkumar C, Foley M, Francis D, Al-Lamee R. Remote digital smart device follow-up in prospective clinical trials: early insights from ORBITA-2, ORBITA-COSMIC, and ORBITA-STAR. European Heart Journal Supplements 2022;24(Supplement_H):H32 View
  8. Thrush P, Vogel C. Cardiac rehabilitation in pediatric cardiomyopathy. Progress in Pediatric Cardiology 2018;49:43 View
  9. Gori T. Restenosis after Coronary Stent Implantation: Cellular Mechanisms and Potential of Endothelial Progenitor Cells (A Short Guide for the Interventional Cardiologist). Cells 2022;11(13):2094 View